Company: BDRX
Filing Date: 2025-11-03
Form Type: 6-K
Source: 0001214659-25-015739
Chunk: 1

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-03
Form: 6-K
Chunk 1
---
 EMA of its pivotal Phase 3 Serenta trial of eRapa in patients with FAP, a copy of which
is attached to this Form 6-K as Exhibit 99.1.

The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

<div align='center'>SUBMITTED HEREWITH</div>

Attached to the Registrant’s Form 6-K filing
for the month of November 2025 is:

<div align='center'>SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: November 3, 2025 | Biodexa Pharmaceuticals PLC 
 By:                         | /s/ Stephen Stamp                                   |
|:-----------------------|:----------------------------|:----------------------------------------------------|
|                        |                             | Stephen Stamp                                       |
|                        |                             | Chief Executive Officer and Chief Financial Officer |